Latest From Organogenesis Inc.
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
M&A deal activity waned in March, with a total of 9 deals completed in the month, down from 12 in February and 17 in March 2016. This third month brought the total number of deals for Q1 2017 to 33, a significant year-on-year decline compared to 51 in the first quarter of 2016.
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Organogenesis Inc.
- Senior Management
Gary S Gillheeny, Sr., Pres. & CEO
Timothy M Cunningham, CFO
Brian Grow, Chief Commercial Officer
Patrick Bilbo, COO
Howard Walthall, EVP, Strategy & Mkt. Dev.
- Contact Info
Phone: (781) 575-0775
85 Dan Rd.
Canton, MA 02021
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.